Delafloxacin
- Generic Name
- Delafloxacin
- Brand Names
- Baxdela, Quofenix
- Drug Type
- Small Molecule
- Chemical Formula
- C18H12ClF3N4O4
- CAS Number
- 189279-58-1
- Unique Ingredient Identifier
- 6315412YVF
- Background
Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and...
- Indication
Delafloxacin is indicated for the treatment of acute bacterial skin and skin structure infections caused by the Gram-positive organisms Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Strept...
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00719810
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Physician Alliance Research Center, Anaheim, California, United States
🇺🇸Tri City Medical Center, Oceanside, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.